UK. Observation studies of OPM suggest substantially lower mortality than IPM data in National HF audits. This suggests observation bias.

Aims: To determine: (i) if there has been expansion in OPM service in UK centres; (ii) what proportion of patients are treated with OPM; (iii) what proportion of HF service has clinical psychology support; and (iv) feasibility of conducting a multicentre randomised controlled trial (RCT) in the UK to test safety and cost-effectiveness of OPM.

Methods

Results

The ‘AHF-IN or OUT-Survey’ was sent using Survey Monkey software via the UK HF Investigators Research Network and local Clinical Research Network to hospitals in the UK in 2021. 53 responded and estimated 25,485 patients with AHF receive inpatient care per year - median 600 per site [IQR 295,800]. 2730 patients (median 50 [7,100] per site) are treated per year with OPM, representing 9.7% of the total population of patients who had AHF. 67% (35 of 53) centres provided access to OPM. Of the 17 which do not (33%), 11 of these hope to develop this service while 4 do not know if they should develop this service. Two sites had no intention to develop this service. 4 provide Subcutaneous (SC) diuretics only whilst the majority (31) provide IV diuretic service, including 9 which can deliver both IV and SC diuretic service. 28 provide Hospital based OPM (‘frusemide lounge’/ambulatory care centre). There are 8 community-based services and 12 sites can deliver parenteral diuretics at home (figure 2).

Table 1 shows details of the healthcare professionals who administer outpatient based IV diuretic treatment. Only 19% (10) have clinical psychology service; whilst 75% (39) do not. 6% (3) of respondents are not sure if they have clinical psychology service. We are planning a multicentre RCT to test if indeed OPM of AHF is safe, cost-effective, improves wellbeing and hope. 3573 patients are eligible to take part in the SAFE-RCT over 2 years - median 64 per site [33,100]. 1501 can be randomised within 2 years (median 20 per site [30,50]).

Conclusions

Outpatient based IV diuretic therapy is gaining popularity in the UK. Only a small minority of hospitals have clinical psychology service for patients who suffer from HF. Before further rapid expansion of outpatient based IV diuretic service in the UK, a multicentre RCT is urgently needed to test the safety and cost-effectiveness of this innovative service. Importantly, there also needs to be expansion of clinical psychology service alongside in order to provide patients with excellent whole person care.

Conflict of Interest

No

Abstract 133 Table 1  Who administers outpatient based IV diuretic treatment?

<table>
<thead>
<tr>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Community IV team&quot;</td>
<td>8</td>
</tr>
<tr>
<td>Ambulatory team</td>
<td>3</td>
</tr>
<tr>
<td>Cardiac outpatient nurses</td>
<td>1</td>
</tr>
<tr>
<td>District nurse</td>
<td>2</td>
</tr>
<tr>
<td>Heart failure specialist nurse</td>
<td>17</td>
</tr>
<tr>
<td>rapid response team</td>
<td>1</td>
</tr>
</tbody>
</table>

Community

Hospital 20

Home 4

Abstract 133 Figure 1  Ways to provide outpatient based acute heart failure treatment

1Reham Awad, 2Robert Jones, 3Omar Assaf, 4Abdullah Abdullah, 5Alison Seed, 6CJ Cassidy, 7Lesley Howard, 2Suzanne Wong, 2Rebecca Taylor, 3John Cleland, 4Deirdre Lane, 5G Davis, 3Pierpaolo Pellicori, 3Rhiannon Berry, 3Kenneth Wong, 2Blackpool Teaching Hospitals NHS Foundation Trust (Blackpool Victoria Hospital); Blackpool, UK; 2Blackpool Victoria Hospital; 1University of Glasgow; UK; 4Liverpool Centre for Cardiovascular Science, University of Liverpool, UK; 5School of Medicine, University of Central Lancashire, Preston, UK; 6Heartfelt Technologies Ltd, Cambridge, UK; 7Blackpool Teaching Hospitals

Introduction

In England and Wales, heart failure (HF) was the primary diagnosis for >81,000 hospital admissions in 2016-17, with a 30-day readmission rate of nearly 20%. The National HF Audit reports that half of these admissions were associated with moderate or severe peripheral oedema. Conventionally, leg oedema is assessed and graded by a healthcare professional (HCP). A serial measurement of weight is an alternative method of assessing water retention at home but this relies on patient compliance. The Heartfelt device uses high-resolution cameras to generate 3D images of the lower legs and calculates volumes with a precision of about 20mLs without the need for active patient input. Linking Artificial Intelligence algorithms may then be applied to inform either the patient or a healthcare professional of appropriate actions.

Methods

The Lancashire Objective Volume Evaluation of leg oedema in Heart Failure (LOVE-HF) artificial intelligence research programme consists of two pilot randomised controlled, cross-over trials (each with 30 patients and 30 day assessment periods), a registry and screening log (the latter to permit comparison of baseline characteristics to ensure generalisability).
Patients with HF who received IV diuretics (within <6 months) or with peripheral oedema despite receiving at least 80 mg/day of oral furosemide (or equivalent), will be enrolled in LOVE-HF (comparing the Heartfelt device on top of standard care to standard care: figure 1) and LOVE-HF-2 (comparing the Heartfelt device to weight monitoring: figure 2). The efficacy outcome of interest is ‘number of days alive out of hospital’. Secondary outcomes include serious adverse events, quality of life, mental wellbeing, hopelessness scores and HF-symptoms.

These vanguard trials will determine the feasibility of data-collection and confirm estimates of event rates that will inform the design of a substantial multi-centre trial (GLOVE-HF: GLocal Objective Volume Evaluation of oedema in Heart Failure) to determine the clinical utility of the Heartfelt device.
AN IMPROVED EJECTION FRACTION PARAMETER CAPABLE OF REPRESENTING CARDIAC FUNCTION REGARDLESS OF HEART MORPHOLOGY TO DISTINGUISH HFPEF FROM NORMAL HEARTS

Choon Hwai Yap, Yu Zheng, Wei Xuan Chan, Christopher Charles, Mark Richards, Smita Sampath, Asad Abu Bakar Ali, Hwa Liang Leo. Imperial College London, London, UK; National University of Singapore; Merck Sharp & Dohme

Background Ejection Fraction (EF) has been an important parameter describing cardiac function, because of earlier work demonstrating its correlation with outcomes. However, during conditions such as Heart Failure preserved ejection fraction (HFpEF), EF fails to distinguish HFpEF from healthy patients. There are further reports that EF can be skewed by the geometry of the heart, and Heart Failure (HF) can present a wide variety of cardiac morphologies due to remodelling. The reason for the poor performance of EF and its dependency on geometry is unclear, and it is further unclear if such geometric changes from HF remodelling affects cardiac function. We strive to address this here, and derive an improve and simple EF parameter to resolve this.

Methods We developed a simple discretized numerical model to relate incompressible myocardial strains to stroke volume. We used data from two porcine animal models of heart failure, one for HFpEF and one for HF reduced EF (HFrEF), and literature clinical measurements to inform our model. We used the model to test the effects of geometric changes relevant to HF on the ability of the heart to convert myocardial strains to flow function.

Results Our animal models showed that cardiac dilation and wall thickening are primary features relevant to HF. Further investigation via our numerical model showed that wall thickening with no change to strain artificially increased EF, while cardiac dilation with no change to strain artificially decreased EF, demonstrating that EF can be skewed by geometric